DUBLIN--(BUSINESS WIRE)--The "Drug
analysis: omecamtiv mecarbil" drug pipelines has been added to ResearchAndMarkets.com's
offering.
Omecamtiv mecarbil is a novel cardiac myosin
activator that increases contractility in heart muscle through
selectively activating the enzyme myosin ATPase. This results in
increased cardiac contractility without impacting intracellular calcium,
unlike many currently available inotropic agents. Changes in
intracellular calcium are thought to be associated with adverse clinical
effects in heart failure patients.
Cytokinetics' strong
strategic partnerships with larger companies such as Amgen has placed
omecamtiv mecarbil in an ideal position to have optimum market
penetration in the US, Japan, and EU. The drug's ability to increase
contractility without affecting intracellular calcium places it at a
clear advantage to other inotropic agents such as digoxin, usage of
which has declined due to safety issues associated with changes in
intracellular calcium. Despite this promising mode of action, which may
reduce side effects, Amgen will still need to provide strong clinical
data in order to convince physicians of its benefit.
Key
Topics Covered:
List of Figures
Figure
1: Omecamtiv mecarbil for chronic heart failure - SWOT analysis
Figure
2: Drug assessment summary of omecamtiv mecarbil for chronic heart
failure
Figure 3: Drug assessment summary of omecamtiv mecarbil for
chronic heart failure
Figure 4: Omecamtiv mecarbil sales for
chronic heart failure across the US, Japan, and five major EU markets,
by country, 2017-26
List of Tables
Table
1: Omecamtiv mecarbil drug profile
Table 2: Omecamtiv mecarbil
Phase III study in chronic heart failure
Table 3: Omecamtiv
mecarbil Phase II data in chronic heart failure
Table 4: Omecamtiv
mecarbil sales for chronic heart failure across the US, Japan, and five
major EU markets, by country ($m), 2017-26
For more
information about this drug pipelines report visit https://www.researchandmarkets.com/research/bd5s4m/2018_omecamtiv?w=4
2018 Omecamtiv Mecarbil Drug Analysis - ResearchAndMarkets.com
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Cardiovascular
Drugs